Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases

Reports of Bone Scan Index (BSI) calculations as imaging biomarkers to predict survival in patients with metastatic castration-resistant prostate cancer (mCRPC) have been mainly from retrospective studies. To evaluate the effectiveness of enzalutamide (ENZ) in Japanese patients with mCRPC and bone m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirano, Hisashi, Nagata, Masayoshi, Nagaya, Naoya, Nakamura, So, Ashizawa, Takeshi, Lu, Yan, Kawano, Haruna, Kitamura, Kosuke, Sakamoto, Yoshiro, Fujita, Kazuhiko, Isobe, Hideyuki, Tsujimura, Akira, Muto, Satoru, Horie, Shigeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226993/
https://www.ncbi.nlm.nih.gov/pubmed/37248346
http://dx.doi.org/10.1038/s41598-023-35790-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226993/
https://www.ncbi.nlm.nih.gov/pubmed/37248346
http://dx.doi.org/10.1038/s41598-023-35790-5

Ejemplares similares